Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin InhibitorMarketBeat · Oct 13, 2026
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes TranscriptSeeking Alpha · Oct 13, 2026
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in DiabetesGlobeNewsWire · Oct 13, 2026
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in DiabetesGlobeNewsWire · Oct 7, 2026
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 2, 2026
Caspian Therapeutics Unveils KO-7246 at EASD as a Potential Best-In-Class Menin Inhibitor for DiabetesGlobeNewsWire · Sep 29, 2026Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 12, 2026 | -$0.88 | -$0.77 | Beat |
| May 12, 2026 | -$0.88 | -$0.83 | Beat |
| Mar 5, 2026 | -$0.72 | -$0.92 | Miss |
| Nov 4, 2025 | -$0.57 | -$0.85 | Miss |
| Aug 7, 2025 | $0.15 | -$0.75 | Miss |
| May 1, 2025 | -$0.51 | -$0.66 | Miss |